{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Shi Y"],"funding":["China National Major Project for New Drug Innovation","Qilu Pharmaceutical Co., Ltd."],"pagination":["72"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9960473"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["21(1)"],"pubmed_abstract":["<h4>Background</h4>Iruplinalkib (WX-0593) is an anaplastic lymphoma kinase (ALK)/c-ros oncogene 1 (ROS1) tyrosine kinase inhibitor. Here we reported the single-arm, phase II study (INTELLECT) results of the efficacy and safety of iruplinalkib for ALK-positive crizotinib-resistant advanced non-small cell lung cancer (NSCLC) patients.<h4>Methods</h4>ALK-positive crizotinib-resistant advanced NSCLC patients aged ≥18 years, with Eastern Cooperative Oncology Group performance status of 0-2 were eligible. Patients received iruplinalkib 180 mg orally once daily for a 21-day cycle with a 7-day lead-in phase at 60 mg orally once daily. The primary endpoint was the independent review committee (IRC)-assessed objective response rate (ORR).<h4>Results</h4>From August 7, 2019, to October 30, 2020, 146 "],"journal":["BMC medicine"],"pubmed_title":["Efficacy and safety of iruplinalkib (WX-0593) in ALK-positive crizotinib-resistant advanced non-small cell lung cancer patients: a single-arm, multicenter phase II study (INTELLECT)."],"pmcid":["PMC9960473"],"funding_grant_id":["2017ZX09304015"],"pubmed_authors":["Hu Y","Si M","Shan J","Zhang H","Hao X","Zhang L","Zhang S","Zhao Y","Shi Y","Wang L","Wang M","Liu Y","Sun S","Wang X","Gu K","Wang Z","Zhao J","Yu Y","Li H","Kang X","Yang L","Chen J","Hang X","Tan B","Yang W","Hu C","Zhang Z","Geng H","Zhang Y","Yang R","Liu C"],"additional_accession":[]},"is_claimable":false,"name":"Efficacy and safety of iruplinalkib (WX-0593) in ALK-positive crizotinib-resistant advanced non-small cell lung cancer patients: a single-arm, multicenter phase II study (INTELLECT).","description":"<h4>Background</h4>Iruplinalkib (WX-0593) is an anaplastic lymphoma kinase (ALK)/c-ros oncogene 1 (ROS1) tyrosine kinase inhibitor. Here we reported the single-arm, phase II study (INTELLECT) results of the efficacy and safety of iruplinalkib for ALK-positive crizotinib-resistant advanced non-small cell lung cancer (NSCLC) patients.<h4>Methods</h4>ALK-positive crizotinib-resistant advanced NSCLC patients aged ≥18 years, with Eastern Cooperative Oncology Group performance status of 0-2 were eligible. Patients received iruplinalkib 180 mg orally once daily for a 21-day cycle with a 7-day lead-in phase at 60 mg orally once daily. The primary endpoint was the independent review committee (IRC)-assessed objective response rate (ORR).<h4>Results</h4>From August 7, 2019, to October 30, 2020, 146 ","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Feb","modification":"2026-07-14T22:31:02.081Z","creation":"2025-02-19T00:13:59.354Z"},"accession":"S-EPMC9960473","cross_references":{"pubmed":["36829154"],"doi":["10.1186/s12916-023-02738-5"]}}